Changes in US stocks | BeiGene (ONC.US) surged more than 9%, revenue increased 46% in the first half of 2025

The Zhitong Finance App learned that on Tuesday, BeiGene (ONC.US) surged more than 9% to $334.20. Financial reports show that in the first half of 2025, BeiGene achieved total revenue of 17.518 billion yuan, an increase of 46.03% over the previous year, of which product revenue was 17.36 billion yuan, an increase of 45.8% over the previous year; the company achieved net profit of 450 million yuan. This is also the first time since this year that BeiGene turned a loss into a profit.

In the first half of 2025, the company's product revenue growth was due to increased sales of self-developed products Baiyueze® (zebutinib capsules) and Baizean® (tiralizumab), as well as increased sales of Amgen authorized products. Among them, zebutinib, a core self-developed product, has outstanding performance and has been ranked first in the US and global BTK inhibitor markets.

In the first half of 2025, global sales of zebutinib reached 12.527 billion yuan, an increase of 56.2% over the previous year. In the US market, sales of this product reached 8.958 billion yuan, an increase of 51.7% over the previous year. Zebutinib was rapidly adopted by patients and physicians across the US due to its best-in-class clinical features. Zebutinib is not only the product with the largest market share in the US, but also the fastest growing brand product.